• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NRXP

NRXP

NRx Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD4.05

-0.57 (-12.34%)

Rating:C+

Company Profile

CEO

Jonathan C. Javitt

IPO Date

2017-12-04

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.61

Prev. Close

$4.62

Day Low

$3.45

Day High

$4.29

52W Low

$1.62

52W High

$5.05

Market Cap

$0.07B

Volume

4.56M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

79.5%

Avg Negative

2.0%

Avg Neutral

18.4%

News Feed

NRx Pharma Stock Gains On Emergency Use Nod For Zyesami To Treat COVID-19 Patients In Nation Of Georgia

Benzinga·7/27/2021·↑ positive

NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia

PRNewsWire·7/27/2021·↑ positive

NRX Pharmaceuticals Climbs Higher After FDA News, Could See A Breakout Soon

Benzinga
·7/23/2021
·↑ positive

NRXP Stock Increases Over 25% Pre-Market: Why It Happened

Pulse2·7/23/2021·↑ positive

Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?

Benzinga·7/23/2021·↑ positive

NRXP Stock Increased 42.86% After Hours: Why It Happened

Pulse2·7/23/2021·↑ positive

NRXP Stock: This Covid-19 Treatment Could Prime NRx Pharmaceuticals for Big Gains

InvestorPlace·7/22/2021·↑ positive

NRXP Stock Increased Over 80% Intraday: Why It Happened

Pulse2·7/22/2021·↑ positive

Why NRx Pharmaceuticals Stock Is Soaring Today

The Motley Fool·7/22/2021·↑ positive

NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval

PRNewsWire·7/22/2021·↑ positive